Log In
Print
BCIQ
Print
Print this Print this
 

Invega Sustenna paliperidone palmitate

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionIntramuscular injection of paliperidone, a metabolite of risperidone, given once every 3 months
Molecular Target Monoamine receptors
Mechanism of ActionMonoaminergic receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationSchizophrenia
Indication DetailsTreat schizophrenia
Regulatory Designation

Partner

Alkermes plc


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today